Anti-Pyruvate Dehydrogenase E1-alpha subunit antibody [8D10E6] (ab110334)




Our Abpromise guarantee covers the use of ab110334 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-Fr Use at an assay dependent concentration. PubMed: 25223649
WB Use a concentration of 0.5 - 1 µg/ml. Predicted molecular weight: 43 kDa.
ICC/IF Use a concentration of 1 µg/ml. (heat-induced antigen-retrieval improves signal)
Flow Cyt Use a concentration of 1 µg/ml. ab170190-Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.


  • FunctionThe pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2). It contains multiple copies of three enzymatic components: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and lipoamide dehydrogenase (E3).
  • Tissue specificityUbiquitous.
  • Involvement in diseaseDefects in PDHA1 are a cause of pyruvate decarboxylase E1 component deficiency (PDHE1 deficiency) [MIM:312170]. PDHE1 deficiency is the most common enzyme defect in patients with primary lactic acidosis. It is associated with variable clinical phenotypes ranging from neonatal death to prolonged survival complicated by developmental delay, seizures, ataxia, apnea, and in some cases to an X-linked form of Leigh syndrome (X-LS).
    Defects in PDHA1 are the cause of X-linked Leigh syndrome (X-LS) [MIM:308930]. X-LS is an early-onset progressive neurodegenerative disorder with a characteristic neuropathology consisting of focal, bilateral lesions in one or more areas of the central nervous system, including the brainstem, thalamus, basal ganglia, cerebellum, and spinal cord. The lesions are areas of demyelination, gliosis, necrosis, spongiosis, or capillary proliferation. Clinical symptoms depend on which areas of the central nervous system are involved. The most common underlying cause is a defect in oxidative phosphorylation. LS may be a feature of a deficiency of any of the mitochondrial respiratory chain complexes.
  • Cellular localizationMitochondrion matrix.
  • Information by UniProt
  • Database links
  • Alternative names
    • ODPA_HUMAN antibody
    • PDH antibody
    • PDHA antibody
    • PDHA1 antibody
    • PDHCE1A antibody
    • PDHE1 A type I antibody
    • PDHE1-A type I antibody
    • PHE1A antibody
    • Pyruvate Dehydrogenase (lipoamide) alpha 1 antibody
    • Pyruvate dehydrogenase complex, E1 alpha polypeptide 1 antibody
    • Pyruvate Dehydrogenase E1 alpha antibody
    • Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial antibody
    see all

Anti-Pyruvate Dehydrogenase E1-alpha subunit antibody [8D10E6] images

  • All lanes : Anti-Pyruvate Dehydrogenase E1-alpha subunit antibody [8D10E6] (ab110334) at 1 µg/ml

    Lane 1 : Isolated mitochondria from Human heart at 5 µg
    Lane 2 : Isolated mitochondria from Bovine heart at 1 µg
    Lane 3 : Isolated mitochondria from Rat heart at 10 µg
    Lane 4 : Isolated mitochondria from Mouse heart at 10 µg
    Lane 5 : HepG2 cell lysate at 20 µg

    Predicted band size : 43 kDa
  • Immunocytochemistry analysis using ab110334 at 1µg/ml staining Pyruvate Dehydrogenase E1-alpha subunit in HeLa cells (4% paraformaldehyde fixed and Triton X-100 permeabilized).
    The secondary antibody was (green) Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution. DAPI was used to stain the cell nuclei (blue).
  • Flow cytometric analysis using ab110334 at 1µg/ml staining Pyruvate Dehydrogenase E1-alpha subunit in HL60 cells (blue). Isotype control antibody (red).

References for Anti-Pyruvate Dehydrogenase E1-alpha subunit antibody [8D10E6] (ab110334)

This product has been referenced in:
  • Davoudi M  et al. Complex I function and supercomplex formation are preserved in liver mitochondria despite progressive complex III deficiency. PLoS One 9:e86767 (2014). WB ; Mouse . Read more (PubMed: 24466228) »
  • Caro-Maldonado A  et al. Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells. J Immunol 192:3626-36 (2014). Read more (PubMed: 24616478) »

See all 14 Publications for this product

Product Wall

Application Western blot
Sample Euglena Cell lysate - whole cell (Euglena gracilis SM-ZK)
Gel Running Conditions Reduced Denaturing (10)
Loading amount 15 µg
Treatment silencing of pyruvate dehydrogenase E1-alpha subunit or not
Specification Euglena gracilis SM-ZK
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C

Abcam user community

Verified customer

Submitted Jul 07 2016

Thank you for contacting us.

We unfortunately do not provide free samples, this is why we have 100% Abtrial offer. If this antibody does not work you will still be getting a free antibody with Abtrial code.

Please let me know if you a...

Read More

Thank you for contacting us.

This product ab110330 was tested with Mouse, Rat, Cow and Human samples only; horse was never tried. We can however predict, it will be fine for horse samples as well because the horse protein (http://www.uniprot....

Read More

Thank you for contacting us. I am sorry that these antibodies are no longer working properly. I will be happy to help you resolve this issue if you can please provide some additional details about your experiment?

1.) What application were yo...

Read More

Thank you for contacting us.

I found the original order for these ordered on July 28 2011. Since these antibodies are recommended to be stored at 4C, they only have a shelf-life of roughly 1 yr. If the end-user is seeing decreased signal and t...

Read More

Thank you for contacting us. It was nice talking to you.

As discussed on phone I am happy to provide you 5% discount for purchase of any one of the discussed product + free ab123069
Will be happy to provide 4, 100% Abreview discount code...

Read More